Last reviewed · How we verify
NCT05918250
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 1 trial testing mRNA-2736 in Relapsed or Refractory Multiple Myeloma. Withdrawn.
27 May 2026
Quick facts
| Lead sponsor | ModernaTX, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 15 August 2023 |
| Primary completion | 27 May 2026 |
| Estimated completion | 27 May 2026 |
| Sites | 13 locations across Canada, United States |
Drugs / interventions tested
- mRNA-2736 — full drug profile →
Conditions studied
- Relapsed or Refractory Multiple Myeloma — all drugs for Relapsed or Refractory Multiple Myeloma →
Sponsor
ModernaTX, Inc. — full company profile →
Who can join
18 and older, any sex, with Relapsed or Refractory Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed to evaluate the safety and tolerability of mRNA-2736 in participants with RRMM.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
RNA-Based Therapeutic Strategies in Multiple Myeloma: From Molecular Targets to Delivery and Clinical Translation.
Baranov MV, Shalik I, Tsvetkova A, Streltsova A, et al · · 2026 · cited 1× · PMID 41596492 · DOI 10.3390/ijms27020843
Verify or expand the search:
- PubMed search for NCT05918250
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Relapsed or Refractory Multiple Myeloma
Currently open trials in the same condition.
- NCT07369895 — Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07116616 — A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
- NCT07312188 — A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT06604715 — A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT06574568 — A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
Other ModernaTX, Inc. trials
Trials by the same sponsor.
- NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
- NCT07478952 — A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age · Phase 1 · recruiting
- NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
- NCT07116616 — A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
- NCT07117487 — A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05918250 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ModernaTX, Inc.
- Last refreshed: 18 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05918250.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing